156 related articles for article (PubMed ID: 32788108)
1. Performance of
Robin P; van Es N; Le Roux PY; Rondina M; Lecumberri R; Beckers M; Le Gal G; Salaun PY
Thromb Res; 2020 Oct; 194():153-157. PubMed ID: 32788108
[TBL] [Abstract][Full Text] [Related]
2. Screening for occult malignancy with FDG-PET/CT in patients with unprovoked venous thromboembolism.
Alfonso A; Redondo M; Rubio T; Del Olmo B; Rodríguez-Wilhelmi P; García-Velloso MJ; Richter JA; Páramo JA; Lecumberri R
Int J Cancer; 2013 Nov; 133(9):2157-64. PubMed ID: 23616232
[TBL] [Abstract][Full Text] [Related]
3. Performance of 18F-fluorodesoxyglucose positron-emission tomography combined with low-dose computed tomography for cancer screening in patients with unprovoked venous thromboembolism.
Robin P; Le Roux PY; Lacut K; Planquette B; Prévot-Bitot N; Lavigne C; Pastre J; Merah A; Le Gal G; Salaun PY
PLoS One; 2017; 12(6):e0178849. PubMed ID: 28570648
[TBL] [Abstract][Full Text] [Related]
4. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.
Robin P; Kumar S; Salaun PY; Le Roux PY; Couturaud F; Planquette B; Merah A; Roy PM; Thavorn K; Le Gal G
Thromb Res; 2018 Nov; 171():97-102. PubMed ID: 30268859
[TBL] [Abstract][Full Text] [Related]
5. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.
Robin P; Le Roux PY; Planquette B; Accassat S; Roy PM; Couturaud F; Ghazzar N; Prevot-Bitot N; Couturier O; Delluc A; Sanchez O; Tardy B; Le Gal G; Salaun PY;
Lancet Oncol; 2016 Feb; 17(2):193-199. PubMed ID: 26672686
[TBL] [Abstract][Full Text] [Related]
6.
Delluc A; Robin P
Thromb Res; 2022 May; 213 Suppl 1():S42-S45. PubMed ID: 36210560
[No Abstract] [Full Text] [Related]
7. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism.
Robin P; Le Roux PY; Le Moigne E; Planquette B; Prévot-Bitot N; Roy PM; Pastre J; Merah A; Couturaud F; Le Gal G; Salaun PY
Thromb Res; 2017 Jul; 155():6-9. PubMed ID: 28460260
[No Abstract] [Full Text] [Related]
8. A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism.
Rondina MT; Wanner N; Pendleton RC; Kraiss LW; Vinik R; Zimmerman GA; Heilbrun M; Hoffman JM; Morton KA
Thromb Res; 2012 Jan; 129(1):22-7. PubMed ID: 21802118
[TBL] [Abstract][Full Text] [Related]
9. Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism.
Robin P; Otten HM; Delluc A; van Es N; Carrier M; Salaün PY; Le Gal G
Thromb Res; 2018 Nov; 171():92-96. PubMed ID: 30268858
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography combined with computed tomography as a screening tool for occult malignancy in patients with unprovoked venous thromboembolism: an observational study.
Chauchard M; Benali K; Papo T; Sacre K
Medicine (Baltimore); 2014 Nov; 93(21):e110. PubMed ID: 25380083
[TBL] [Abstract][Full Text] [Related]
11. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.
Robertson L; Yeoh SE; Stansby G; Agarwal R
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010837. PubMed ID: 28832905
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of
Caspersen KB; Giannoutsou N; Gerke O; Alavi A; Høilund-Carlsen PF; Hess S
Ann Nucl Med; 2019 Mar; 33(3):184-192. PubMed ID: 30569441
[TBL] [Abstract][Full Text] [Related]
13. Performance of 18F fluoro-2-désoxy-D-glucose positron emission tomography/computed tomography for the diagnosis of venous thromboembolism.
Le Roux PY; Robin P; Delluc A; Tardy B; Abgral R; Couturaud F; Reffad A; Le Gal G; Salaun PY
Thromb Res; 2015 Jan; 135(1):31-5. PubMed ID: 25455997
[TBL] [Abstract][Full Text] [Related]
14. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of F-18 FDG PET or PET/CT for detection of lymph node metastasis in clinically node negative head and neck cancer patients; A systematic review and meta-analysis.
Kim SJ; Pak K; Kim K
Am J Otolaryngol; 2019; 40(2):297-305. PubMed ID: 30473166
[TBL] [Abstract][Full Text] [Related]
16. Venous thromboembolism and occult cancer: impact on clinical practice.
Gheshmy A; Carrier M
Thromb Res; 2016 Apr; 140 Suppl 1():S8-11. PubMed ID: 27067984
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging for Predicting Venous Thromboembolism in Children With Lymphoma.
Beall M; Deep K; Tram NK; Nabavinia M; Janse SA; Chou TH; Hardisky D; Bobbey AJ; Kerlin BA; Audino AN; Stacy MR
Circ Cardiovasc Imaging; 2023 Apr; 16(4):e014992. PubMed ID: 37013817
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of glioma.
Shaw TB; Jeffree RL; Thomas P; Goodman S; Debowski M; Lwin Z; Chua B
J Med Imaging Radiat Oncol; 2019 Oct; 63(5):650-656. PubMed ID: 31368665
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of diffusion-weighted imaging and
Noij DP; Martens RM; Zwezerijnen B; Koopman T; de Bree R; Hoekstra OS; de Graaf P; Castelijns JA
Eur J Radiol; 2018 Oct; 107():20-25. PubMed ID: 30292267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]